Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
Open Access
- 8 June 2020
- Vol. 12 (6), 1511
- https://doi.org/10.3390/cancers12061511
Abstract
In recent years, neoadjuvant treatment trials have shown that breast cancer subtypes identified on the basis of genomic and/or molecular signatures exhibit different response rates and recurrence outcomes, with the implication that subtype-specific treatment approaches are needed. Estrogen receptor-positive (ER+) breast cancers present a unique set of challenges for determining optimal neoadjuvant treatment approaches. There is increased recognition that not all ER+ breast cancers benefit from chemotherapy, and that there may be a subset of ER+ breast cancers that can be treated effectively using endocrine therapies alone. With this uncertainty, there is a need to improve the assessment and to optimize the treatment of ER+ breast cancers. While pathology-based markers offer a snapshot of tumor response to neoadjuvant therapy, non-invasive imaging of the ER disease in response to treatment would provide broader insights into tumor heterogeneity, ER biology, and the timing of surrogate endpoint measurements. In this review, we provide an overview of the current landscape of breast imaging in neoadjuvant studies and highlight the technological advances in each imaging modality. We then further examine some potential imaging markers for neoadjuvant treatment response in ER+ breast cancers.Funding Information
- National Institutes of Health (R01CA227763)
- U.S. Department of Defense (BC17123)
This publication has 192 references indexed in Scilit:
- Radiomics: Extracting more information from medical images using advanced feature analysisEuropean Journal of Cancer, 2012
- Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerNature Reviews Clinical Oncology, 2012
- Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imagingEuropean Radiology, 2010
- Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research toolBritish Journal of Cancer, 2010
- Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancerThe American Journal of Surgery, 2010
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancerBritish Journal of Cancer, 2009
- Contrast-enhanced digital mammographyEuropean Journal of Radiology, 2009
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002